Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS:

* Diagnosis of indolent B-cell non-Hodgkin's lymphoma of 1 of the following subtypes:

  * Follicular (grade 1, 2, or 3)
  * Marginal zone (extranodal, nodal, or splenic)
* CD20-positive disease
* Relapsed or progressive disease after prior anti-neoplastic therapy, as indicated by 1 of the following:

  * New lesions
  * Objective evidence of progression of existing lesions
* Complete response ≥ 6 months in duration after prior rituximab therapy\* NOTE: \*For patients who were previously treated with a regimen that included rituximab
* At least 1 measurable lymph node mass \> 1.5 cm in 2 perpendicular dimensions that has not been irradiated OR that has progressed since prior radiotherapy
* No active CNS lymphoma

PATIENT CHARACTERISTICS:

Age

* 18 and over

Performance status

* Karnofsky 50-100% OR
* ECOG 0-2

Life expectancy

* Not specified

Hematopoietic

* Absolute neutrophil count ≥ 1,000/mm\^3
* Platelet count ≥ 50,000/mm\^3

Hepatic

* AST and ALT ≤ 3 times upper limit of normal (ULN)
* Bilirubin ≤ 2 times ULN

Renal

* Creatinine ≤ 2 mg/dL OR
* Creatinine clearance ≥ 30 mL/min

Immunologic

* No known anaphylaxis or immunoglobulin E-mediated hypersensitivity to murine proteins or to any component of rituximab, including polysorbate 80 and sodium citrate dihydrate
* No active systemic infection requiring treatment
* No history of allergic reaction attributable to compounds containing boron or mannitol

Other

* No peripheral neuropathy or neuropathic pain ≥ grade 2
* No other malignancy within the past 5 years except completely resected basal cell or squamous cell skin cancer or an in situ malignancy

  * Previously diagnosed prostate cancer allowed provided the following criteria are met:

    * T1-2a, N0, M0 disease AND Gleason score ≤ 7 AND prostate specific antigen (PSA) ≤ 10 ng/mL before initial therapy
    * Treated with definitive curative therapy (i.e., prostatectomy or radiotherapy) within the past 2 years
    * No clinical evidence of prostate cancer AND undetectable PSA (for prostatectomy patients) or PSA \< 1 ng/mL (for patients who did not undergo prostatectomy)
* No serious medical or psychiatric illness that would preclude study participation
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

* See Disease Characteristics
* More than 10 weeks since prior radioimmunoconjugates or toxin immunoconjugates (e.g., ibritumomab tiuxetan or iodine I 131 tositumomab)
* More than 4 weeks since prior rituximab, alemtuzumab, or other unconjugated therapeutic antibody
* No concurrent prophylactic bone marrow growth factors (e.g., filgrastim \[G-CSF\], sargramostim \[GM-CSF\], or epoetin alfa) during course 1 of study therapy

Chemotherapy

* More than 6 weeks since prior nitrosoureas
* No concurrent cisplatin

Endocrine therapy

* No concurrent corticosteroids (e.g., dexamethasone) except prednisone ≤ 15 mg/day or equivalent for adrenal insufficiency

Radiotherapy

* See Disease Characteristics
* See Biologic therapy
* More than 3 weeks since prior radiotherapy
* No concurrent radiotherapy

Surgery

* More than 2 weeks since prior major surgery

Other

* Recovered from all prior therapy
* No prior bortezomib
* More than 3 weeks since prior antineoplastic therapy
* More than 3 weeks since prior experimental therapy
* No other concurrent antineoplastic therapy
* No other concurrent investigational agents

  * Concurrent participation in a non-treatment study allowed provided it does not interfere with participation in this study